Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study

Statistics in Medicine

Volumn 35, Issue 26, 2016, Pages 4824-4836

  Mi, Xiaojuan ^a   Hammill, Bradley G ^a,b   Curtis, Lesley H ^a,b   Lai, Edward Chia Cheng ^c   Setoguchi, Soko ^d,e  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

immortal time bias; landmark methods; Monte Carlo simulations; observational study; survival analysis; time varying treatment

Indexed keywords

ARTICLE; CALCULATION; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; IMMORTAL PERSON TIME BIAS; LANDMARK METHOD; MANTEL BYAR METHOD; MATHEMATICAL COMPUTING; MONTE CARLO METHOD; SIMULATION; STATISTICAL PARAMETERS; STUDY DESIGN; CHRONIC OBSTRUCTIVE LUNG DISEASE; HUMAN; STATISTICAL BIAS; TIME FACTOR; TREATMENT OUTCOME;

BIAS; COMPARATIVE EFFECTIVENESS RESEARCH; HUMANS; MONTE CARLO METHOD; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84976870093     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.7019     Document Type: Article

References (26)

1. Suissa S. Immortal time bias in pharmacoepidemiology. American Journal of Epidemiology 2008; 167:492–499.
2. Walker AM. Observation and Inference: An Introduction to the Methods of Epidemiology. Epidemiology Resources Inc: Newton Lower Falls, Massachusetts, 1991.
3. Levesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 2010; 340:b5087.
4. Renoux C, Suissa S. Immortal time bias in the study of effectiveness of interferon-beta in multiple sclerosis. Annals of Neurology 2008; 64:109–110.
5. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiology and Drug Safety 2007; 16:241–249.
6. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. American Journal of Respiratory and Critical Care Medicine 2003; 168:49–53.
7. Mantel N, Byar DP. Evaluation of response-time data involving transient states: an illustration using heart-transplant data. Journal of the American Statistical Association 1974; 69:81–86.
8. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology (3rd edn). Wolters Kluwer Health/Lippincott Williams & Wilkins: Philadelphia, 2008.
9. Austin PC, Mamdani MM, van Walraven C, Tu JV. Quantifying the impact of survivor treatment bias in observational studies. Journal of Evaluation in Clinical Practice 2006; 12: 601-612.
10. Liu J, Weinhandl ED, Gilbertson DT, Collins AJ, St Peter WL. Issues regarding ‘immortal time’ in the analysis of the treatment effects in observational studies. Kidney International 2012; 81:341–350.
11. Anderson J, Cain K, Gelber R. Analysis of survival by tumor response. Journal of Clinical Oncology 1983; 1:710–719.
12. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007; 297:159–168.
13. Malenka DJ, Kaplan AV, Lucas FL, Sharp SM, Skinner JS. Outcomes following coronary stenting in the era of bare-metal vs the era of drug-eluting stents. JAMA 2008; 299:2868–2876.
14. Kramer MCA, Van der Wal AC, Koch KT, Ploegmakers JP, Van der Schaaf RJ, Henriques JPS, Baan J, Rittersma SZH, Vis MM, Piek JJ, Tijssen De Winter RJ. Presence of older thrombus is an independent predictor of long-term mortality in patients with ST-elevation. Circulation 2008; 118:1810–1816.
15. Mi X, Hammill BG, Curtis LH, Greiner MA, Setoguchi S. Impact of immortal person-time and time scale in comparative effectiveness research for medical devices: a case for implantable cardioverter–defibrillators. Journal of Clinical Epidemiology 2013; 66:S138–S144.
16. Austin PC. A comparison of 12 algorithms for matching on the propensity score. Statistics in Medicine 2014; 33:1057–1069.
17. Leemis LM, Shih LH, Reynertson K. Variate generation for accelerated life and proportional hazards models with time dependent covariates. Statistics & Probability Letters 1990; 10:335–339.
18. Burton A, Altman DG, Royston P, Holder RL. The design of simulation studies in medical statistics. Statistics in Medicine 2006; 25:4279–4292.
19. Cohen J. Statistical Power Analysis for the Behavioral Sciences (2nd edn). Erlbaum: Hillsdale, NJ, 1988.
20. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. American Journal of Respiratory and Critical Care Medicine 2003; 168(1):49–53.
21. Genao L, Durheim MT, Mi X, Todd JL, Whitson HE, Curtis LH. Early and long-term outcomes of older adults following acute care encounters for chronic obstructive pulmonary disease exacerbation. Annals of the American Thoracic Society 2015; 12(12):1805–1812.
22. Bourbeau J, Rouleau MY, Boucher S. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax 1998; 53:477–482.
23. Normand SL. Evaluating the optimal timing of angiography: landmark or off the mark? Circulation 2007; 116:2656–2657.
24. Chen CY, Stevenson LW, Stewart GC, Bhatt DL, Desai M, Seeger JD, Williams L, Jalbert JJ, Setoguchi S. Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: cohort study of older patients with heart failure. BMJ 2015; 351:h3529. doi:10.1136/bmj.h3529.
25. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70:41–55.
26. Rubin DB, Thomas N. Matching using estimated propensity scores: relating theory to practice. Biometrics 1996; 52:249–264.